Stock comparison
Moderna, Inc. is 3.7x more valuable than REPLIGEN CORP by market capitalization ($30.38 B vs $8.12 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 3.7x more valuable than REPLIGEN CORP by market capitalization ($30.38 B vs $8.12 B).
Market value leader
MRNA
Moderna, Inc. is 3.7x more valuable than REPLIGEN CORP by market capitalization ($30.38 B vs $8.12 B).
Revenue leader
MRNA
RGEN: $738.26M vs MRNA: $1.94B.
Profit leader
RGEN
RGEN: $48.89M vs MRNA: -$2.82B.
Margin leader
RGEN
RGEN: 6.6% vs MRNA: -145.2% net margin.
| Metric | RGEN | MRNA |
|---|---|---|
| Market cap | $8.12 B | $30.38 B |
| US-listed rank | #1079 | #461 |
| Revenue (latest FY) | $738.26M | $1.94B |
| Net income (latest FY) | $48.89M | -$2.82B |
| Net margin | 6.6% | -145.2% |
| P/E (trailing FY) | 166.1x | - |
| SEC filings | 1,331 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 3.7x more valuable than REPLIGEN CORP by market capitalization ($30.38 B vs $8.12 B).
In their latest fiscal years, REPLIGEN CORP reported $738.26M in revenue while Moderna, Inc. reported $1.94B.
Full pages: REPLIGEN CORP and Moderna, Inc., or browse the full rankings.